| abstract |
Pyridine and pyrimidine compounds: (I); or one of its pharmaceutically acceptable salts, in which m, n, R1, R2, R3, R4, R5, R6, R7, X1, X2, X3, X4, X5, X6, X7, X8, and Y are as defined in this memory; (II) or one of its pharmaceutically acceptable salts, in which ring A is as defined in the specification, and (III), or one of its pharmaceutically acceptable salts, in which m, n, and, R2, R3, R4, R5, R6, R7, R9, X ', X2, and ring A are as defined in this specification; the compositions containing them and the processes for the preparation of said compounds. Methods for treating treatable disorders or diseases are also provided herein by inhibiting PDE1O, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive compulsive disorder and the like. |